Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDA Orange Book
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Imunovir
2. Inosiplex
3. Isoprinosin
4. Isoprinosine
5. Methisoprinol
6. Methysoprinol
7. Metisoprinol
8. Npt 10381
9. Npt-10381
10. Npt10381
11. Pranobex, Inosine
1. Isoprinosine
2. 36703-88-5
3. Inosiplex
4. Delimmun
5. Methisoprinol
6. Imunovir
7. Isoviral
8. Viruxan
9. Isoprinosin
10. Isoprinosina
11. Aviral
12. Inosine Acedobene Dimepranol
13. Imunoviral
14. Modimmunal
15. Immunovir
16. Pranosina
17. Pranosine
18. Np 113
19. Npt-10381
20. W1so0v223f
21. Np-113
22. Inosine Pranobex (jan)
23. Inosine-2-hydroxypropyldimethylammonium 4-acetamidobenzoate (1:3)
24. Inosine Pranobex [jan]
25. 4-acetamidobenzoic Acid,9-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3h-purin-6(9h)-one,1-(dimethylamino)propan-2-ol (3:1:3)
26. 4-acetamidobenzoic Acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol
27. Inosine Pranobex [ban:jan]
28. Einecs 253-162-1
29. Ntp 10381
30. Unii-w1so0v223f
31. Groprinosin
32. Isoprinosine (tn)
33. Inosine, Compd. With 1-(dimethylamino)-2-propanol 4-(acetylamino)benzoate (salt) (1:3)
34. Inosine, Compound With (2-hydroxypropyl)dimethylammonium P-acetamidobenzoate (1:3)
35. Inosine Pranobex [mi]
36. Chembl3833327
37. Inosine Pranobex [mart.]
38. Inosine Pranobex [who-dd]
39. Dtxsid401021342
40. Iad
41. Mfcd05662374
42. S5016
43. Akos025312516
44. Akos030228417
45. Ccg-270642
46. As-12319
47. Hy-107801
48. Cs-0030676
49. I1037
50. C74892
51. D01995
52. 703i885
53. A874300
54. Q3130053
55. P-acetamidobenzoic Salt Of N,n-dimethylamino-2-propanol & Inosine (3:1)
56. Inosine & 1-(dimethylamino)-2-propanol & 4-(acetylamino)benzoate (salt) (1:3:3)
57. 4-acetamidobenzoic Acid; 9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1h-purin-6-one; 1-(dimethylamino)propan-2-ol
58. 4-acetamidobenzoic Acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-purin-6-one;1-(dimethylamino)propan-2-ol
Molecular Weight | 1115.2 g/mol |
---|---|
Molecular Formula | C52H78N10O17 |
Hydrogen Bond Donor Count | 13 |
Hydrogen Bond Acceptor Count | 22 |
Rotatable Bond Count | 14 |
Exact Mass | 1114.55464106 g/mol |
Monoisotopic Mass | 1114.55464106 g/mol |
Topological Polar Surface Area | 399 Ų |
Heavy Atom Count | 79 |
Formal Charge | 0 |
Complexity | 658 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 3 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 7 |
Adjuvants, Immunologic
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)
Antiviral Agents
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)
J - Antiinfectives for systemic use
J05 - Antivirals for systemic use
J05A - Direct acting antivirals
J05AX - Other antivirals
J05AX05 - Inosine pranobex
ICE Pharma offers a unique range of bile acid products and best-in-class services for the pharmaceutical industry.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
ABOUT THIS PAGE
A Inosine Pranobex manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Inosine Pranobex, including repackagers and relabelers. The FDA regulates Inosine Pranobex manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Inosine Pranobex API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Inosine Pranobex manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Inosine Pranobex supplier is an individual or a company that provides Inosine Pranobex active pharmaceutical ingredient (API) or Inosine Pranobex finished formulations upon request. The Inosine Pranobex suppliers may include Inosine Pranobex API manufacturers, exporters, distributors and traders.
click here to find a list of Inosine Pranobex suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Inosine Pranobex Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Inosine Pranobex GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Inosine Pranobex GMP manufacturer or Inosine Pranobex GMP API supplier for your needs.
A Inosine Pranobex CoA (Certificate of Analysis) is a formal document that attests to Inosine Pranobex's compliance with Inosine Pranobex specifications and serves as a tool for batch-level quality control.
Inosine Pranobex CoA mostly includes findings from lab analyses of a specific batch. For each Inosine Pranobex CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Inosine Pranobex may be tested according to a variety of international standards, such as European Pharmacopoeia (Inosine Pranobex EP), Inosine Pranobex JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Inosine Pranobex USP).
LOOKING FOR A SUPPLIER?